Lv3
232 积分 2024-07-11 加入
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy
3天前
已完结
Pathophysiology and therapeutic options for cirrhotic portal hypertension
4天前
已完结
Renal Complications in Portal Hypertension
4天前
已关闭
Interaction of inflammation and portal hypertension in cirrhosis progression
4天前
已完结
Vascular mechanotransduction
2个月前
已完结
Molecular Mechanisms of Increased Intrahepatic Resistance in Portal Hypertension
2个月前
已关闭
Endothelin receptor antagonists in chronic kidney disease
2个月前
已完结
Metabolic dysfunction-associated steatotic liver disease and its link to cancer
4个月前
已完结
Pathophysiology and therapeutic options for cirrhotic portal hypertension
4个月前
已完结
The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease
5个月前
已完结
皖公网安备34019202002308
